TheraVitae Claims Another Cardiomyopathy Treatment Success with Adult Stem Cells August 27, 2007
Posted by TheraVitae in : Press Releases , trackbackSpokane, Washington 8/27/2007 8:29 AM GMT (TransWorldNews - Top Story) Citing Amy Banner, a young wife and mother with cardiomyopathy from Spokane,Washington, Theravitae believes its adult stem cell therapy has measurable clinical benefits that can only be attributed to their cardiomyopathy treatment. Just one month after receiving VesCell in Bangkok Heart Hospital, Amy had her first follow-up appointment with her hometown cardiologist to learn the following clinical results:
Firstly, the report on her Premature Ventricular Contractions (PVCs) as recorded by her pacemaker. These contractions are like an extra heartbeats coming from an irritable area in the struggling ventricles and indicate rhythm disturbances. Prior to stem cell therapy Amy was experiencing some 35,000 uncomfortable PVCs a month. In the last month she recorded only 2200. “No wonder I am feeling so good!” she said. “This alone made it all worthwhile and now I don’t even notice them they are so mild, or maybe they are happening in my sleep.”
Secondly, Amy’s cardiologist told her that her heart had shrunk from 8.7cm to 8cm and that as the left ventricle shrunk further her Ejection Fraction, which measures the ability of the ventricle to pump blood to her body, would rise further as efficiency increased.
Thirdly, Amy had a BNP blood test which measures a secretion in the ventricle indicating the degree of heart failure. From a dangerous level of 3000 she was told it now was 190 – almost in the normal range.For Amy the clinical measurements just added weight to how she was feeling. “The bottom line is that I feel great. I have way more energy. My mom is no longer doing my housework and laundry for me. I can walk and play with my seven-year old daughter. Everything is running along very smoothly,” she said. Prior to stem cell therapy Amy could do little and as she deteriorated even small things like taking a shower or washing her hair became more of a challenge.
Theravitae is determined to lay to rest the myth that all such severely ill heart patients can look forward to is a gradual decline in the quality of life, suffering, dependence on a cocktail of drugs and an early death. The more patients can demonstrate clinically measurable improvements the more the medical establishment will be forced to face the fact that objective measures do not lie.
Contact:
Don Margolis
Founder, Theravitae
(215)-764-6312
e-mail: coo@theravitae.com
